Clinical Trial Update: Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

This report summarizes the completed Phase 1 dose-escalation safety study of TL32711 in adults with refractory solid tumors or lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• TL32711

Snippet

Sponsor: TetraLogic Pharmaceuticals | Conditions: Cancer | Phase 1 | Status: COMPLETED